More on IRD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.05 |
|
|||
| Open | $4.12 | ||||
| 52 Wk High | $0.02 | ||||
| 52 Wk Low | $0.02 | ||||
| Day High | $4.13 | ||||
| Day Low | $3.75 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,530,122 | ||||
- FDA approves Opus Genetics' eye drop RYZUMVI for presbyopia
- Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
- Opus Genetics (IRD) Reiterated at Market Outperform by Citizens on Key Learnings from BEST1 Cohort
- Form 8-K Opus Genetics, Inc. For: Oct 14
- Opus Genetics reports gene therapy trial data for two eye diseases
- Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
- Opus Genetics to Present at the Chardan Annual Healthcare Conference
- Form 4 Opus Genetics, Inc. For: Sep 30 Filed by: Foundation Fighting Blindness Retinal Degeneration Fund
- Form 4 Opus Genetics, Inc. For: Sep 09 Filed by: Magrath George
- Form 8-K Opus Genetics, Inc. For: Sep 11
Entities mentioned with IRD
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- Show More...
